Trimodality treatment in gastric and gastroesophageal junction cancers: Current approach and future perspectives.

World J Gastrointest Oncol · 2022 · PMC8790425 · PMID 35116110

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

In subgroup analysis, patients with node-negative disease at diagnosis and patients with squamous histology received clear benefit, while patients with adenocarcinoma showed a clear trend towards improvement[ 57 ].

also in 19,460 other papers

did not reach statistical significanceno p-value reported

Median OS was higher in the chemotherapy group vs the chemoradiotherapy group (43 mo vs 37 mo) although this difference did not reach statistical significance in any subgroup[ 44 ].

also in 111,027 other papers

showed a trendno p-value reported

Newer retrospective data also suggested a similar pattern for gastric and GEJ cancer[ 23 , 24 ], while results from the prospective trials cited below showed a trend for improved outcomes in patients achieving complete response in preoperative therapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.